Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | AVPR1B | P47901 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10161833 | 0.94 | ALDH1A1 (0.42) | CNR2NPC1RAB9AALDH1A1AVPR1B | |
| SCHEMBL10132830 | 0.85 | CNR2 (0.41) | CNR2ALDH1A1AVPR1BLMNACNR1 | |
| SCHEMBL10132642 | 0.82 | SMO (0.43) | SMN1; SMN2ALDH1A1KMT2ARXFP1LMNA | |
| SCHEMBL10132694 | 0.81 | PKM (0.42) | SMN1; SMN2RXFP1LMNAPOLB | |
| SCHEMBL13284135 | 0.80 | TNKS (0.45) | AVPR1B | |
| SCHEMBL10163309 | 0.79 | CNR2 (0.40) | CNR2AVPR1BKMT2ACD274 | |
| SCHEMBL10132798 | 0.78 | TUBB4A (0.41) | SMN1; SMN2RAB9AALDH1A1KMT2ARXFP1 | |
| SCHEMBL10132814 | 0.77 | MEN1 (0.47) | ALDH1A1KMT2ALMNAPOLB | |
| SCHEMBL10132656 | 0.76 | TUBB4A (0.40) | SMN1; SMN2RXFP1LMNAPOLB | |
| SCHEMBL10132846 | 0.76 | ABCB1 (0.44) | SMN1; SMN2NPC1RAB9AALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741917-B2 | Benzo [C] phenanthridines as antimicrobial agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2014-06-03 | — | — | US | disclosed |
| US-20120022061-A1 | BENZO [C] PHENANTHRIDINES AS ANTIMICROBIAL AGENTS | RUGTERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022061-A1 | BENZO [C] PHENANTHRIDINES AS ANTIMICROBIAL AGENTS | CCNT1, XPO4, XDH | CNR2 2323/4885SMN1; SMN2 3202/4885NPC1 2668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.